# US 2021/0332142 A1 · Tie2-binding agents and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332142 A1
- Document ID: US20210332142A1
- Status: Published application
- Kind: A1
- Application number: 17/208,292
- Filed: 2021-03-22
- Published: 2021-10-28
- Earliest claimed: 2020-03-24
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Minhong YAN; Gu ZHANG; Nicholas John AGARD; Danielle Marie DICARA; Philip E. HASS; Julie Q. HANG; Erin L. CHRISTENSEN; Robert Paul MORSE; Sarah SANOWAR; Vittal SHIVVA
- Web page: https://patentgrep.com/patent/US20210332142A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 27/02: Ophthalmic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/61: containing an enzyme fusion for detection (lacZ, luciferase)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.

## Claims

### Claim 1

An isolated antibody or antigen-binding fragment thereof that specifically binds to Tie2, wherein the antibody or fragment thereof comprises:
a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence NTDIS (SEQ ID NO:3), (b) CDR-H2 comprising the amino acid sequence RISPSDGNTYYADSVKG (SEQ ID NO:4), and (c) CDR-H3 comprising the amino acid sequence RTRWASX1AX2DY (SEQ ID NO:5), where X1 is M, L, K, F, Y, R, N, Q, H or W and/or or X2 is F, Y L, Q, I, K, or H, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence RASQDVSTAVA (SEQ ID NO:8), (e) CDR-L2 comprising the amino acid sequence SASFLYS (SEQ ID NO:9), and (f) CDR-L3 comprising the amino acid sequence QQSYTTPPT (SEQ ID NO:10).

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, wherein the CDR-H3 comprises the amino acid sequence RTRWASWAMDY (SEQ ID NO:6).

### Claim 3 (depends on 1, 2)

The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein the CDR-H3 comprises the amino acid sequence RTRWASWAFDY (SEQ ID NO:7).

### Claim 4

The antibody or antigen-binding fragment thereof of any one of the preceding claims, which is a monoclonal antibody, a humanized antibody, an antibody fragment, and/or a chimeric antibody.

### Claim 5

The antibody or antigen-binding fragment thereof of any one of the preceding claims, which is a Fab fragment that binds Tie2.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody or antigen-binding fragment thereof of any one of claims 1 to 5, comprising a VL domain comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:21 and a VH domain comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:20.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The antibody or antigen-binding fragment thereof of any one of claims 1 to 6, comprising a VL domain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:21 and a VH domain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:20.

### Claim 8

The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the antibody comprises the VL sequence of SEQ ID NO:21 and a VH sequence of SEQ ID NO:20.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The antibody or antigen-binding fragment thereof of any one of claims 1 to 8, wherein the antibody comprises an engineered cysteine, wherein
the engineered cysteine is selected from a T120C, G166C, G178C, T187C, and T209C in the HC; or
the engineered cysteine is selected from Q124C, R142C, Q155C, L201C, T206C, K107C, K126C, and K149C in the LC;
wherein the residue number of the engineered cysteine is according to EU numbering.

### Claim 10 (depends on 9)

The antibody or antigen-binding fragment thereof of claim 9, wherein the engineered cysteine is selected from T209C in the HC and T206C in the LC.

### Claim 11 (depends on 9, 10)

The antibody or antigen-binding fragment thereof of claim 9 or 10, wherein the engineered cysteine is T206C in the LC.

### Claim 12 (depends on 9, 10)

The antibody or antigen-binding fragment thereof of claim 9 or 10, wherein the engineered cysteine is T209C in the HC.

### Claim 13

The antibody or antigen-binding fragment thereof of any one of the preceding claims, comprising a LC comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:25 and a HC comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:55.

### Claim 14

The antibody or antigen-binding fragment thereof of any one of the preceding claims, comprising a LC comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:25 and a HC comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:55.

### Claim 15

The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the antibody comprises a LC comprising the sequence of SEQ ID NO:25 and a HC comprising the sequence of SEQ ID NO:55.

### Claim 16

The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the HC constant regions terminates at position 221 (EU numbering).

### Claim 17

An antibody or antigen-binding fragment thereof that specifically binds to Tie-2 wherein the antibody comprises a HC sequence of SEQ ID NO:55 and a LC sequence of SEQ ID NO:25.

### Claim 18

An antibody or antigen-binding fragment thereof that specifically binds to Tie-2 wherein the antibody comprises a HC sequence of SEQ ID NO:23 and a LC sequence of SEQ ID NO:56.

### Claim 19

An isolated nucleic acid encoding the antibody or antigen-binding fragment thereof of any of the preceding claims.

### Claim 20 (depends on 19)

A host cell comprising the nucleic acid of claim 19.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A conjugate that binds to Tie2, wherein the conjugate comprises at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight antibodies or antigen-binding fragment thereof according to any one of claims 1 to 18, wherein each of the antibodies or antigen-binding fragment thereof is linked to a multimerizing moiety.

### Claim 22 (depends on 21)

The conjugate of claim 21, wherein the conjugate causes a reduction in Tie2 protein levels in an in vitro assay by less than 25%, less than 50% or less than 75%.

### Claim 23 (depends on 21, 22)

The conjugate of claim 21 or 22, wherein the conjugate does not cause a reduction in Tie-2 protein levels in an in vitro assay by more than 25%, more than 50%, or more than 75%.

### Claim 24 (depends on 21, 22, 23)

The conjugate of any one of claims 21 to 23, wherein the multimerizing moiety comprises a polyol, a polypeptide, and/or a peptide.

### Claim 25 (depends on 21, 22, 23, 24)

The conjugate of any one of claims 21 to 24, wherein the multimerizing moiety comprising a polyol, wherein the polyol is a multi-armed polyol, selected from a dimer, a tetramer, a hexamer, and an octamer.

### Claim 26 (depends on 25)

The conjugate of claim 25, wherein the multi-armed polyol is a hexamer.

### Claim 27 (depends on 24, 25, 26)

The conjugate of any one of claims 24 to 26, wherein the polyol is a polyethylene glycol (PEG).

### Claim 28 (depends on 24, 25, 26, 27)

The conjugate of any one of claims 24 to 27, wherein the polyol is covalently linked to the at least two antibodies or antigen-binding fragment thereof through a free sulfhydryl group of an engineered cysteine amino acid, wherein the engineered cysteine is selected from the group consisting of
T120C, G166C, G178C, T187C, and T209C in the HC; or
the engineered cysteine is selected from the group consisting of Q124C, R142C, Q155C, L201C, T206C, K107C, K126C, and K149C in the LC;
wherein the residue number is according to EU numbering.

### Claim 29 (depends on 28)

The conjugate of claim 28, wherein the engineered cysteine is T206C in the LC, wherein the residue number is according to EU numbering.

### Claim 30 (depends on 28)

The conjugate of claim 28, wherein the engineered cysteine is T209C in the HC, wherein the residue number is according to EU numbering.

### Claim 31 (depends on 25, 26, 27)

The conjugate of any one of claims 25 to 27, wherein the polyol is covalently linked to the at least one antibody through a free amino group of a lysine amino acid.

### Claim 32 (depends on 27, 28, 29, 30, 31)

The conjugate according to any one of claims 27 to 31, wherein the PEG has a weight average molecular weight of from about 500 Daltons (Da) to about 300,000 Da.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 27, 28, 29, 30, 31, 32)

The conjugate according to any one of claims 27 to 32, wherein the PEG has the structure of general formula (Ib):
where each m is independently an integer from 3-250; each R1 is independently either absent or is a linking group; and each R2 is independently either hydrogen or a terminal reactive group;
where at least one R2 is a terminal reactive group and is covalently linked to the antibody or antigen-binding fragment thereof of any one of claims 1 to 14.

### Claim 34 (depends on 33)

The conjugate according to claim 33, wherein at least one R1 is a linking group, wherein R1 and R2 when taken together are selected from:
and combinations thereof; wherein each i is independently an integer of 0-10; j is an integer of 0-10; and R2 is a terminal reactive group selected from the group consisting of a thiol reactive group, an amino reactive group, and combinations thereof.

### Claim 35 (depends on 33, 34)

The conjugate according to claim 33 or claim 34, wherein at least 1 R2 is a maleamide and is covalently linked to the antibody or antigen-binding fragment thereof.

### Claim 36 (depends on 33, 34, 35)

The conjugate according to any one of claims 33 to 35, wherein each R2 is a maleamide.

### Claim 37

A conjugate which binds Tie2 comprising:
a Fab comprising a HC having SEQ ID NO:55 and a LC having SEQ ID NO:25; conjugated to a polyol which has the structure of Formula 1(b)
where each m is independently an integer from 20-30, where R1 and R2 taken together has the structure
where R2 is a maleamide; and
wherein the polyol is linked to the Fab HC at residue C209 (EU numbering).

### Claim 38 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A pharmaceutical composition comprising the conjugate according to any one of claims 21 to 37 and a pharmaceutically acceptable carrier.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38, further comprising an additional therapeutic agent, wherein the additional therapeutic agent is selected from the group consisting of a VEGF antagonist, an Ang2 antagonist, an HtrA1 antagonist, and IL33 antagonist, a complement component antagonist, and a second Tie2 agonist.

### Claim 40 (depends on 38, 39)

A long acting delivery device for ocular delivery comprising the pharmaceutical composition of claim 38 or 39 and a means for delivering the composition intravitreally to a patient, wherein the composition remains effective on site for a prolonged period of time.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A method of treating a Tie2 pathway-mediated disorder in a subject in need thereof, comprising administering to the subject an effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1 to 18, the conjugate of any one of claims 21 to 36, or the pharmaceutical composition of any one of claims 37 to 38.

### Claim 42 (depends on 41)

The method of claim 41, wherein the Tie2 pathway-mediated disorder is a vascular permeability disorder.

### Claim 43 (depends on 41, 42)

The method of claim 41 or 42, wherein the Tie2 pathway-mediated disorder is an eye condition.

### Claim 44 (depends on 43)

The method of claim 43, wherein the eye condition is selected from diabetic macular edema (DME), diabetic retinopathy, age-related macular degeneration (AMD), including dry and wet (non-exudative and exudative) forms, choroidal neovascularization (CNV), uveitis, ischemia-related retinopathy, pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, Central Retinal Vein Occlusion (CRVO), corneal neovascularization, glaucoma, and retinal neovascularization.

### Claim 45 (depends on 43, 44)

The method of claim 43 or 44, wherein the eye condition is DME.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The antibody of any one of claims 1 to 18 or the conjugate of any one of claims 21 to 39 for use as a medicament.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The antibody of any one of claims 1 to 18 or the conjugate of any one of claims 21 to 39 for use in treating a Tie2 pathway-mediated disorder and/or an ocular disorder in a subject in need thereof.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

Use of the antibody of any one of claims 1 to 18 or the conjugate of any one of claims 21 to 39 in the manufacture of a medicament for the treatment of a Tie2 pathway-mediated disorder and/or an ocular disorder in a subject in need thereof.
